Literature DB >> 2948384

Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia.

F R Davey, A S Kurec, R H Tomar, J R Smith.   

Abstract

The concentrations of serum immunoglobulins were correlated to the stage of disease and the proportions of peripheral blood lymphocyte subsets in 25 untreated patients with B-cell chronic lymphocytic leukemia (CLL). Diminished levels of at least one serum immunoglobulin were present in 77% of all patients with CLL and 73% of patients with Stage 0 disease. The mean concentration of IgG, IgM, and IgA decreased with advancing stage of CLL. The percentages of total T, T-helper (TH), and T-suppressor (TS) cells in the peripheral blood were less in patients with CLL than in healthy persons, but the absolute concentrations of total T, TH, and TS cells were greater in patients with CLL than controls (P less than 0.02). The absolute number of B-cells (P less than 0.01) and null cells (P less than 0.001) was also increased in patients with CLL, particularly those patients in advanced stages of CLL. These findings suggest that the hypogammaglobulinemia associated with CLL first occurs during the earliest stage of disease and may be related to the alterations in the proportion of peripheral blood lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2948384     DOI: 10.1093/ajcp/87.1.60

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

2.  Biclonal Gammopathy in Chronic Lymphocytic Leukemia: Case Report and Review of the Literature.

Authors:  Nafila Al-Riyami; Khalil Al-Farsi; Khalfan Al-Amrani; Sameera Al-Harrasi; Mohammed Al-Huneini; Salam Al-Kindi
Journal:  Oman Med J       Date:  2015-05

3.  Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy.

Authors:  Serhat Çelik; Leylagül Kaynar; Zeynep Tuğba Güven; Mustafa Baydar; Muzaffer Keklik; Mustafa Çetin; Ali Ünal; Fatih Demirkan
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-03       Impact factor: 0.900

4.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

Review 5.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

6.  Immune and hormonal changes in early-stage chronic lymphocytic leukemia patients.

Authors:  H Everaus; J Lehtmaa; E Luik; H Kŏdar
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

7.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

8.  Evaluation of Periodontal Parameters in Patients with Early Stage Chronic Lymphocytic Leukemia.

Authors:  Nives Rinčić; Darko Božić; Goran Rinčić; Petar Gaćina; Darije Plančak
Journal:  Acta Stomatol Croat       Date:  2016-03

Review 9.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.

Authors:  Constantin A Dasanu; Doru T Alexandrescu
Journal:  MedGenMed       Date:  2007-11-15

10.  Cancer risk after ABO-incompatible living-donor kidney transplantation.

Authors:  Erin C Hall; Eric A Engels; Robert A Montgomery; Dorry L Segev
Journal:  Transplantation       Date:  2013-09-15       Impact factor: 5.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.